Standard

Arms-qPCR Improves Detection Sensitivity of Earlier Diagnosis of Papillary Thyroid Cancers With Worse Prognosis Determined by Coexisting BRAF V600E and Tert Promoter Mutations. / Yu, Peng-Cheng; Tan, Li-Cheng; Zhu, Xiao-Li; Shi, Xiao; Chernikov, Roman; Semenov, Arseny; Zhang, Ling; Ma, Ben; Wang, Yu; Zhou, Xiao-Yan; Ji, Qing-Hai; Wei, Wen-Jun; Wang, Yu-Long.

в: Endocrine Practice, Том 27, № 7, 07.2021, стр. 698-705.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

Harvard

Yu, P-C, Tan, L-C, Zhu, X-L, Shi, X, Chernikov, R, Semenov, A, Zhang, L, Ma, B, Wang, Y, Zhou, X-Y, Ji, Q-H, Wei, W-J & Wang, Y-L 2021, 'Arms-qPCR Improves Detection Sensitivity of Earlier Diagnosis of Papillary Thyroid Cancers With Worse Prognosis Determined by Coexisting BRAF V600E and Tert Promoter Mutations', Endocrine Practice, Том. 27, № 7, стр. 698-705. https://doi.org/10.1016/j.eprac.2021.01.015

APA

Yu, P-C., Tan, L-C., Zhu, X-L., Shi, X., Chernikov, R., Semenov, A., Zhang, L., Ma, B., Wang, Y., Zhou, X-Y., Ji, Q-H., Wei, W-J., & Wang, Y-L. (2021). Arms-qPCR Improves Detection Sensitivity of Earlier Diagnosis of Papillary Thyroid Cancers With Worse Prognosis Determined by Coexisting BRAF V600E and Tert Promoter Mutations. Endocrine Practice, 27(7), 698-705. https://doi.org/10.1016/j.eprac.2021.01.015

Vancouver

Yu P-C, Tan L-C, Zhu X-L, Shi X, Chernikov R, Semenov A и пр. Arms-qPCR Improves Detection Sensitivity of Earlier Diagnosis of Papillary Thyroid Cancers With Worse Prognosis Determined by Coexisting BRAF V600E and Tert Promoter Mutations. Endocrine Practice. 2021 Июль;27(7):698-705. https://doi.org/10.1016/j.eprac.2021.01.015

Author

Yu, Peng-Cheng ; Tan, Li-Cheng ; Zhu, Xiao-Li ; Shi, Xiao ; Chernikov, Roman ; Semenov, Arseny ; Zhang, Ling ; Ma, Ben ; Wang, Yu ; Zhou, Xiao-Yan ; Ji, Qing-Hai ; Wei, Wen-Jun ; Wang, Yu-Long. / Arms-qPCR Improves Detection Sensitivity of Earlier Diagnosis of Papillary Thyroid Cancers With Worse Prognosis Determined by Coexisting BRAF V600E and Tert Promoter Mutations. в: Endocrine Practice. 2021 ; Том 27, № 7. стр. 698-705.

BibTeX

@article{7deaeb2916bb4edd8f33f39fbd27c4b2,
title = "Arms-qPCR Improves Detection Sensitivity of Earlier Diagnosis of Papillary Thyroid Cancers With Worse Prognosis Determined by Coexisting BRAF V600E and Tert Promoter Mutations",
abstract = "OBJECTIVE: The coexistence of BRAF V600E and the telomerase reverse transcriptase (TERT) promoter mutation C228T/C250T is extensively associated with thyroid cancer prognosis. Our study aimed to establish a sensitive method for mutation detection and explore the correlation in detail.METHODS: The BRAF and TERT promoter mutation status of 250 papillary thyroid cancers was determined using amplification-refractory mutation system quantitative polymerase chain reaction (ARMS-qPCR) and Sanger sequencing to compare the sensitivity of the 2 methods. Associations between the mutation status and clinicopathological features were then analyzed.RESULTS: ARMS-qPCR was more sensitive than Sanger sequencing (BRAF V600E: 75.2% [188 of 250] vs 52.4% [131 of 250], P < .001; TERT promoter C228T/C250T mutation: 12.0% [30 of 250] vs 3.6% [9 of 250], P = .001; comutation: 9.6% [24 of 250] vs 3.2% [8 of 250], P = .005). Both ARMS-qPCR and Sanger sequencing indicated that patients with coexisting BRAF V600E and TERT promoter mutations had an older diagnosis age, higher recurrence rate, and were associated with a more advanced TNM stage and higher metastasis, age, completeness of resection, invasion, and size score. Moreover, ARMS-qPCR helped identify an earlier group stage, which was younger and had smaller tumors and a lower recurrence rate, compared with the group with coexisting BRAF V600E and TERT promoter mutations identified by Sanger sequencing. The newly identified group had a lower metastasis, age, completeness of resection, invasion, and size score and TNM stage.CONCLUSION: Patients with coexisting BRAF V600E and TERT promoter mutations had a worse prognosis. ARMS-qPCR, the more sensitive method, can be used to identify patients who have a potentially worse prognosis earlier.",
keywords = "ARMS-qPCR, BRAF, TERT, thyroid cancer, Carcinoma, Papillary/diagnosis, Prognosis, Early Detection of Cancer, Humans, Neoplasm Recurrence, Local, Proto-Oncogene Proteins B-raf/genetics, Thyroid Cancer, Papillary/genetics, Thyroid Neoplasms/diagnosis, Mutation, Telomerase/genetics, SYSTEM, DNA, HALLMARKS, CARCINOMA",
author = "Peng-Cheng Yu and Li-Cheng Tan and Xiao-Li Zhu and Xiao Shi and Roman Chernikov and Arseny Semenov and Ling Zhang and Ben Ma and Yu Wang and Xiao-Yan Zhou and Qing-Hai Ji and Wen-Jun Wei and Yu-Long Wang",
note = "Publisher Copyright: {\textcopyright} 2021 AACE",
year = "2021",
month = jul,
doi = "10.1016/j.eprac.2021.01.015",
language = "English",
volume = "27",
pages = "698--705",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "7",

}

RIS

TY - JOUR

T1 - Arms-qPCR Improves Detection Sensitivity of Earlier Diagnosis of Papillary Thyroid Cancers With Worse Prognosis Determined by Coexisting BRAF V600E and Tert Promoter Mutations

AU - Yu, Peng-Cheng

AU - Tan, Li-Cheng

AU - Zhu, Xiao-Li

AU - Shi, Xiao

AU - Chernikov, Roman

AU - Semenov, Arseny

AU - Zhang, Ling

AU - Ma, Ben

AU - Wang, Yu

AU - Zhou, Xiao-Yan

AU - Ji, Qing-Hai

AU - Wei, Wen-Jun

AU - Wang, Yu-Long

N1 - Publisher Copyright: © 2021 AACE

PY - 2021/7

Y1 - 2021/7

N2 - OBJECTIVE: The coexistence of BRAF V600E and the telomerase reverse transcriptase (TERT) promoter mutation C228T/C250T is extensively associated with thyroid cancer prognosis. Our study aimed to establish a sensitive method for mutation detection and explore the correlation in detail.METHODS: The BRAF and TERT promoter mutation status of 250 papillary thyroid cancers was determined using amplification-refractory mutation system quantitative polymerase chain reaction (ARMS-qPCR) and Sanger sequencing to compare the sensitivity of the 2 methods. Associations between the mutation status and clinicopathological features were then analyzed.RESULTS: ARMS-qPCR was more sensitive than Sanger sequencing (BRAF V600E: 75.2% [188 of 250] vs 52.4% [131 of 250], P < .001; TERT promoter C228T/C250T mutation: 12.0% [30 of 250] vs 3.6% [9 of 250], P = .001; comutation: 9.6% [24 of 250] vs 3.2% [8 of 250], P = .005). Both ARMS-qPCR and Sanger sequencing indicated that patients with coexisting BRAF V600E and TERT promoter mutations had an older diagnosis age, higher recurrence rate, and were associated with a more advanced TNM stage and higher metastasis, age, completeness of resection, invasion, and size score. Moreover, ARMS-qPCR helped identify an earlier group stage, which was younger and had smaller tumors and a lower recurrence rate, compared with the group with coexisting BRAF V600E and TERT promoter mutations identified by Sanger sequencing. The newly identified group had a lower metastasis, age, completeness of resection, invasion, and size score and TNM stage.CONCLUSION: Patients with coexisting BRAF V600E and TERT promoter mutations had a worse prognosis. ARMS-qPCR, the more sensitive method, can be used to identify patients who have a potentially worse prognosis earlier.

AB - OBJECTIVE: The coexistence of BRAF V600E and the telomerase reverse transcriptase (TERT) promoter mutation C228T/C250T is extensively associated with thyroid cancer prognosis. Our study aimed to establish a sensitive method for mutation detection and explore the correlation in detail.METHODS: The BRAF and TERT promoter mutation status of 250 papillary thyroid cancers was determined using amplification-refractory mutation system quantitative polymerase chain reaction (ARMS-qPCR) and Sanger sequencing to compare the sensitivity of the 2 methods. Associations between the mutation status and clinicopathological features were then analyzed.RESULTS: ARMS-qPCR was more sensitive than Sanger sequencing (BRAF V600E: 75.2% [188 of 250] vs 52.4% [131 of 250], P < .001; TERT promoter C228T/C250T mutation: 12.0% [30 of 250] vs 3.6% [9 of 250], P = .001; comutation: 9.6% [24 of 250] vs 3.2% [8 of 250], P = .005). Both ARMS-qPCR and Sanger sequencing indicated that patients with coexisting BRAF V600E and TERT promoter mutations had an older diagnosis age, higher recurrence rate, and were associated with a more advanced TNM stage and higher metastasis, age, completeness of resection, invasion, and size score. Moreover, ARMS-qPCR helped identify an earlier group stage, which was younger and had smaller tumors and a lower recurrence rate, compared with the group with coexisting BRAF V600E and TERT promoter mutations identified by Sanger sequencing. The newly identified group had a lower metastasis, age, completeness of resection, invasion, and size score and TNM stage.CONCLUSION: Patients with coexisting BRAF V600E and TERT promoter mutations had a worse prognosis. ARMS-qPCR, the more sensitive method, can be used to identify patients who have a potentially worse prognosis earlier.

KW - ARMS-qPCR

KW - BRAF

KW - TERT

KW - thyroid cancer

KW - Carcinoma, Papillary/diagnosis

KW - Prognosis

KW - Early Detection of Cancer

KW - Humans

KW - Neoplasm Recurrence, Local

KW - Proto-Oncogene Proteins B-raf/genetics

KW - Thyroid Cancer, Papillary/genetics

KW - Thyroid Neoplasms/diagnosis

KW - Mutation

KW - Telomerase/genetics

KW - SYSTEM

KW - DNA

KW - HALLMARKS

KW - CARCINOMA

UR - http://www.scopus.com/inward/record.url?scp=85109354803&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/865e0f9b-4389-30cc-9e17-a41e4b57be67/

U2 - 10.1016/j.eprac.2021.01.015

DO - 10.1016/j.eprac.2021.01.015

M3 - Article

C2 - 33515759

VL - 27

SP - 698

EP - 705

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 7

ER -

ID: 75571048